JP7341130B2 - 癌を治療するための組成物および治療方法 - Google Patents

癌を治療するための組成物および治療方法 Download PDF

Info

Publication number
JP7341130B2
JP7341130B2 JP2020517983A JP2020517983A JP7341130B2 JP 7341130 B2 JP7341130 B2 JP 7341130B2 JP 2020517983 A JP2020517983 A JP 2020517983A JP 2020517983 A JP2020517983 A JP 2020517983A JP 7341130 B2 JP7341130 B2 JP 7341130B2
Authority
JP
Japan
Prior art keywords
cancer
treatment
nivolumab
combination
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536068A5 (enExample
JP2020536068A (ja
Inventor
ポール・アンドリュー・バシャーノ
ジャスティン・カミラ・ウォーカー
ペニー・イー・フィリップス
リィ・ジュー
スティーブン・エイチ・バーンスタイン
ジェイムズ・キャシディ
ケイティ・リン・シモンセン
アレクサンダー・アズリレヴィチ
シバニ・スリバスタバ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020536068A publication Critical patent/JP2020536068A/ja
Publication of JP2020536068A5 publication Critical patent/JP2020536068A5/ja
Application granted granted Critical
Publication of JP7341130B2 publication Critical patent/JP7341130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020517983A 2017-09-29 2018-09-28 癌を治療するための組成物および治療方法 Active JP7341130B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762565819P 2017-09-29 2017-09-29
US62/565,819 2017-09-29
US201762569766P 2017-10-09 2017-10-09
US62/569,766 2017-10-09
US201762580219P 2017-11-01 2017-11-01
US62/580,219 2017-11-01
US201762609210P 2017-12-21 2017-12-21
US62/609,210 2017-12-21
US201862642711P 2018-03-14 2018-03-14
US62/642,711 2018-03-14
US201862678490P 2018-05-31 2018-05-31
US62/678,490 2018-05-31
PCT/US2018/053443 WO2019067913A1 (en) 2017-09-29 2018-09-28 COMPOSITIONS AND METHODS OF TREATING CANCER

Publications (3)

Publication Number Publication Date
JP2020536068A JP2020536068A (ja) 2020-12-10
JP2020536068A5 JP2020536068A5 (enExample) 2021-11-04
JP7341130B2 true JP7341130B2 (ja) 2023-09-08

Family

ID=65902748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517983A Active JP7341130B2 (ja) 2017-09-29 2018-09-28 癌を治療するための組成物および治療方法

Country Status (6)

Country Link
US (1) US11351163B2 (enExample)
EP (1) EP3691643A4 (enExample)
JP (1) JP7341130B2 (enExample)
KR (1) KR102760684B1 (enExample)
CN (1) CN111386117A (enExample)
WO (1) WO2019067913A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
JP2018515474A (ja) * 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073770A1 (en) 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO2000037504A2 (en) 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US9107887B2 (en) 2011-03-10 2015-08-18 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015214390B2 (en) * 2014-02-04 2020-05-07 Merck Sharp & Dohme LLC. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
US20170158776A1 (en) * 2014-05-15 2017-06-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
CA2971734C (en) 2014-12-22 2025-11-18 Enumeral Biomedical Holdings Inc Anti-pd-1 antibodies
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
FI3334763T3 (fi) 2015-08-11 2024-10-30 Wuxi Biologics Ireland Ltd Uusia pd-l1-vasta-aineita
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
AU2016349501B2 (en) * 2015-11-04 2022-07-21 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
EP3402512A4 (en) 2016-01-11 2019-09-25 Armo Biosciences, Inc. INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US10731128B2 (en) * 2016-11-22 2020-08-04 Alloplex Biotherapeutics, Inc. Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073770A1 (en) 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cancer Res.，2017年07月01日，77(13_Supplement)，CT116，doi:10.1158/1538-7445.AM2017-CT116
Cell Chem Biol.，2017年09月21日，24(9)，pp.1148-1160
Journal of Clinical Oncology，2017年05月30日，35(15_suppl)，p.5504，doi:10.1200/JCO.2017.35.15_suppl.5504
N Engl J Med.，2016年，375(19)，pp.1856-1867
Onco Targets Ther.，2015年，8，pp.2045-51
Oncology Times，39(5)，2017年03月10日，p.24，doi:10.1097/01.COT.0000514204.42704.df

Also Published As

Publication number Publication date
KR102760684B1 (ko) 2025-01-24
EP3691643A1 (en) 2020-08-12
EP3691643A4 (en) 2021-06-16
WO2019067913A1 (en) 2019-04-04
US11351163B2 (en) 2022-06-07
JP2020536068A (ja) 2020-12-10
US20210030739A1 (en) 2021-02-04
CN111386117A (zh) 2020-07-07
KR20200061382A (ko) 2020-06-02

Similar Documents

Publication Publication Date Title
CN110536703B (zh) 使用抗axl抗体-药物缀合物的组合疗法
CN106456753A (zh) 用于治疗癌症的pd‑1拮抗剂和ido1抑制剂的组合
AU2016274585A1 (en) Methods of treating cancer using anti-OX40 antibodies
JP2020517652A5 (enExample)
US20220160718A1 (en) Compositions and methods of treating cancer
US20230131598A1 (en) Combination treatment for cancer
CN110582303A (zh) 使用抗cd25抗体-药物缀合物的组合疗法
JP2020517629A5 (enExample)
CN115443152A (zh) 使用pd-1拮抗剂、ctla4拮抗剂以及仑伐替尼或其药学上可接受的盐的组合治疗癌症的方法
JP2025118606A (ja) 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
JP7341130B2 (ja) 癌を治療するための組成物および治療方法
JP2021533090A (ja) 併用療法
US20230149543A1 (en) Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
US20190216923A1 (en) Methods and combination therapy to treat cancer
JP2025505642A (ja) Ｅｇｆｒ／ｍｅｔ二重特異性抗体で処置された患者における注入関連反応を低減するための方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230829

R150 Certificate of patent or registration of utility model

Ref document number: 7341130

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150